Compare SPDR Gold Trust (GLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs BIO-TECHNE Corp — how do they compare? SPDR Gold Trust trades at $383.87 (market cap $141.59B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: SPDR Gold Trust is far larger — about 12.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and BIO-TECHNE Corp for 63 Days on average.
| GLD | TECH | |
|---|---|---|
Market Cap | $141.59B | $11.37B |
Volume | 7,008,541 | 3,153,511 |
52-Week High | $495.90 | $72.61 |
52-Week Low | $362.32 | $43.31 |
Typical Hold Time | 74 Days | 63 Days |
Sector | — | Health |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader pressure from rising Treasury yields and a stronger U.S. dollar. The technical picture remains bearish with key support at $372 and resistance at $378. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with weak payrolls data failing to spark a sustained rally.
The outlook for GLD remains challenged by persistent headwinds from elevated interest rates and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed rate hikes and declining investor sentiment, while potential catalysts include geopolitical tensions and inflation concerns.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
